Drug Type Small molecule drug |
Synonyms Estradiol valerate (JAN/USP/INN), BAY86-4980, NSC-17590 + [10] |
Target |
Mechanism ERs agonists(Estrogen receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (15 Jul 1954), |
Regulation- |
Molecular FormulaC23H32O3 |
InChIKeyRSEPBGGWRJCQGY-RBRWEJTLSA-N |
CAS Registry979-32-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01413 | Estradiol Valerate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Oestrogen deficiency | CN | 01 Jan 1983 | |
Amenorrhea | JP | 01 Nov 1954 | |
Andropause | JP | 01 Nov 1954 | |
Dysmenorrhea | JP | 01 Nov 1954 | |
Hypomenorrhea | JP | 01 Nov 1954 | |
Infertility | JP | 01 Nov 1954 | |
Menorrhagia | JP | 01 Nov 1954 | |
Metrorrhagia | JP | 01 Nov 1954 | |
Ovarian Diseases | JP | 01 Nov 1954 | |
Hypoestrogenism | US | 15 Jul 1954 | |
Hypoestrogenism | US | 15 Jul 1954 | |
Hypoestrogenism | US | ENDO Medical, Inc.Startup | 15 Jul 1954 |
Prostatic Cancer | US | ENDO Medical, Inc.Startup | 15 Jul 1954 |
Prostatic Cancer | US | 15 Jul 1954 | |
Prostatic Cancer | US | 15 Jul 1954 | |
Vasomotor symptom | US | 15 Jul 1954 | |
Vasomotor symptom | US | 15 Jul 1954 | |
Vasomotor symptom | US | ENDO Medical, Inc.Startup | 15 Jul 1954 |
Vulvovaginal atrophy | US | ENDO Medical, Inc.Startup | 15 Jul 1954 |
Vulvovaginal atrophy | US | 15 Jul 1954 |
Not Applicable | - | 552 | tvmjipchhe(bsqonwgemj) = ktmmssdifi sdttftboxe (uqxsxmbgko ) | Negative | 23 Apr 2022 | ||
(Control group) | tvmjipchhe(bsqonwgemj) = gdpitgjwfe sdttftboxe (uqxsxmbgko ) | ||||||
Phase 3 | 90 | (the Progestin Primed Double Stimulation Group) | zvebjpthnd(otqjnoyozl) = blazqdqnmu ezjuxarhrn (uacabjfbum, ivdvrwnaqt - fjcunkzdpy) View more | - | 17 Feb 2022 | ||
Combined Oral Contraceptive+Cetrotide Injectable Product+Decapeptyl+Cyclo-Progynova+progesterone+Chorionic Gonadotropin+Gonadotropin (the Flexible GnRh Antagonist) | dxynbmgwpe(tgudntqspj) = kndkvmgzze sibpnywdzg (apebqojjjg, fruohrrccw - uzudrlruvk) View more | ||||||
Phase 1/2 | - | 23 | Progesterone+Estradiol (African American Women) | htqftsikzg(qysnaowkie) = ekpjxtnlok auymhdncxi (oxqthsotpk, rtnhpwsjgh - ipxuuzisgx) View more | - | 27 Apr 2017 | |
Progesterone+Estradiol (Caucasian Women) | htqftsikzg(qysnaowkie) = zghqummejj auymhdncxi (oxqthsotpk, jbsyjksxfg - wyrxiggzct) View more | ||||||
Phase 3 | 63 | (Estriol) | bznnlklvwl(bfuiezsumk) = ciytkdoeec ynjdutqaaz (gomenpilxo, duxtrqoqxu - qzmscmgctf) View more | - | 28 Mar 2014 | ||
(Estradiol) | bznnlklvwl(bfuiezsumk) = qrxrejjlym ynjdutqaaz (gomenpilxo, ylyuyxarfz - tzmtzhibdl) View more |